EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of Rapid Sequential Combination Therapy on Distinct Haemodynamic Measures in Newly Diagnosed Pulmonary Arterial Hypertension

Tilmann Kramer, Phillip Nattmann, Felix Gerhardt, Patrycja Stafiej, Daniel Dumitrescu, Henrik Ten Freyhaus, Max Wißmüller, Christopher Hohmann, Stephan Baldus, Stephan Rosenkranz iD

ESC Heart Failure · 2024

DOI: 10.1002/ehf2.14611 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Tilmann Kramer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln, Cologne, Germany. Hauptthemen laut MEDLINE: Hemodynamics, Drug Therapy, Combination, Phosphodiesterase 5 Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Actelion Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

In pulmonary arterial hypertension (PAH), upfront combination therapy with ERA and PDE5i is associated with a reduction in morbidity and mortality events and improves standard haemodynamics, but data remain limited. Aims of this study were (i) to capture detailed haemodynamic effects of rapid sequential dual combination therapy in patients with newly diagnosed PAH; (ii) to monitor the impact of treatment initiation on clinical variables and patients' risk status, and (iii) to compare the treatment effect in patients with ‘classical PAH’ and ‘PAH with co-morbidities’.

Methods

Fifty patients (median age 57 [42–71] years, 66% female) with newly diagnosed PAH (76% idiopathic) were treated with a PD5i/sGC-S or ERA, followed by addition of the respective other drug class within 4 weeks. All patients underwent repeat right heart catheterization (RHC) during early follow-up.

Results

At early repeat RHC (7 ± 2 months), there were substantial reductions in mean pulmonary artery pressure (mPAP: 52.2 ± 13.5 to 39.0 ± 10.6 mmHg; −25.3%), and pulmonary vascular resistance (PVR: 12.1 ± 5.7 to 5.8 ± 3.1 WU; −52.1%), and an increase in cardiac index (2.1 ± 0.4 to 2.7 ± 0.7 mL/min/m2; +32.2%) (all P < 0.05). Haemodynamic improvements correlated with improved clinical parameters including 6-min walking distance (336 ± 315 to 389 ± 120 m), NTproBNP levels (1.712 ± 2.024 to 506 ± 550 ng/L, both P < 0.05) and WHO-FC at 12 months, resulting in improved risk status, and were found in patients with few (n = 37) or multiple cardiovascular co-morbidities (BMI > 30 kg/m2, hypertension, diabetes, coronary artery disease [≥3]; n = 13), albeit baseline PVR in PAH patients with multiple co-morbidities was lower (9.3 ± 4.4 vs. 13.1 ± 5.9 WU) and PVR reduction less pronounced compared with those with few co-morbidities (−42.7% vs. −54.7%). However, comprehensive haemodynamic assessment considering further variables of prognostic relevance such as stroke volume index and pulmonary artery compliance showed similar improvements among the two groups (SVI: +50.0% vs. +49.2%; PAC: 91.7% vs. 100.0%). Finally, the 4-strata risk assessment approach was better able to capture treatment response as compared with other approaches, particularly in patients with co-morbidities.

Conclusions

Rapid sequential combination therapy with PDE5i/sGC-S and ERA substantially ameliorates cardiopulmonary haemodynamics at early follow-up in patients without, and to a lesser extent, with cardiovascular co-morbidities. This occurs in line with improvements of clinical parameters and risk status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemodynamicsDrug Therapy, CombinationPhosphodiesterase 5 InhibitorsHumansFemaleMaleMiddle AgedAgedAdultPulmonary Arterial HypertensionFollow-Up StudiesTreatment OutcomeCardiac CatheterizationAntihypertensive AgentsVascular ResistanceTime FactorsEndothelin Receptor Antagonists

Stichwörter der Autor:innen

Combination therapyEndothelin receptor antagonistHaemodynamicsPhosphodiesterase type 5 inhibitorPulmonary arterial hypertension (PAH)

Substanzen

Phosphodiesterase 5 InhibitorsAntihypertensive AgentsEndothelin Receptor Antagonists

Autor:innen und Institutionen

  • Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln, Cologne, Germany.
  • Klinik für Allgemeine und Interventionelle Kardiologie, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany.
  • Cologne Cardiovascular Research Center (CCRC), Klinikum der Universität zu Köln, Cologne, Germany.

ORCID-Profile: Stephan Rosenkranz

Förderung

  • Actelion Pharmaceuticals

Zitieren

APA

Kramer, T., Nattmann, P., Gerhardt, F., Stafiej, P., Dumitrescu, D., Ten Freyhaus, H., Wißmüller, M., Hohmann, C., Baldus, S., & Rosenkranz, S. (2024). Impact of Rapid Sequential Combination Therapy on Distinct Haemodynamic Measures in Newly Diagnosed Pulmonary Arterial Hypertension. ESC Heart Failure. https://doi.org/10.1002/ehf2.14611

Vancouver

Kramer T, Nattmann P, Gerhardt F, Stafiej P, Dumitrescu D, Ten Freyhaus H, et al. Impact of Rapid Sequential Combination Therapy on Distinct Haemodynamic Measures in Newly Diagnosed Pulmonary Arterial Hypertension. ESC Heart Failure. 2024. doi:10.1002/ehf2.14611

BibTeX
@article{Kramer2024,
  author = {Kramer, Tilmann and Nattmann, Phillip and Gerhardt, Felix and Stafiej, Patrycja and Dumitrescu, Daniel and Ten Freyhaus, Henrik and Wißmüller, Max and Hohmann, Christopher and Baldus, Stephan and Rosenkranz, Stephan},
  title = {Impact of Rapid Sequential Combination Therapy on Distinct Haemodynamic Measures in Newly Diagnosed Pulmonary Arterial Hypertension},
  journal = {ESC Heart Failure},
  year = {2024},
  doi = {10.1002/ehf2.14611}
}
Kostenlos starten →